EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture| Amgen
Amgen and UCB announced the CHMP's positive opinion for EVENITY (romosozumab) to treat severe osteoporosis in postmenopausal women at high fracture risk. The EC's decision is expected by year-end 2019. EVENITY is already approved in the U.S. and other countries for similar indications.
How this was made
The 30-second read
Why it matters
The positive opinion may trigger a short‑term rally in Amgen shares as investors anticipate expanded market access.
Market read
Regulatory progress for a high‑growth bone‑health drug could materially affect Amgen's valuation and sector dynamics.
What to watch
Competition from other bone‑building agents and reimbursement uncertainties in Europe.
Background
Amgen and UCB co‑developed EVENITY, a monoclonal antibody for severe osteoporosis. The CHMP opinion is a key regulatory step before EU approval.
Ticker impact
CHMP positive opinion on EVENITY could lead to EU marketing authorization, boosting Amgen's European osteoporosis sales.
upward pressure as investors price in potential EU approval and revenue uplift.
Regulatory approval is a material catalyst; the opinion is the first public disclosure and market expects a near‑term EC decision.
Market effects
strengthens the osteoporosis/osteopenia therapeutic segment and may pressure peers.
European biotech market could see increased investor interest in Amgen and similar firms.
Potentially raises Amgen's global revenue outlook and influences global bone‑health drug valuations.
Counterpoint
If the European Commission delays or rejects the authorization, the stock could face disappointment.
Key entities
- CompanyAmgen Inc.
US biotech firm developing EVENITY.
- CompanyUCB
European biotech partner co‑developing EVENITY.
